series-a
Stage
2
Investors
About
AirNexis Therapeutics is developing AN01, a dual PDE3/4 inhibitor currently in Phase 2 clinical trials, targeting treatment for chronic obstructive pulmonary disease (COPD).
Explore AirNexis Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.